Company Profile
IGC Pharma, Inc. Stock Price, News & Catalysts
- Ticker:
- IGC
- Exchange:
- NYSE
- Sector:
- Biopharma
- Location:
- United States
Stock performance
0.27 USD (+0.41%)
Close
Last updated: October 1, 2026
29M USD
Market cap
Why the stock is moving
As of Oct 1, 2026, IGC closed up 0.41% at $0.2700. No new same-company headline was identified in the current news window.
Company overview
Alzheimer's Disease Drug Developer
IGC Pharma develops therapies and digital tools for Alzheimer's disease and related neuropsychiatric symptoms. Its portfolio includes a clinical-stage treatment for agitation and earlier disease-modifying research.
IGC-AD1 for Agitation
IGC-AD1 is an oral formulation being evaluated for agitation in patients with Alzheimer's disease. The Phase 2 CALMA program is intended to assess whether the candidate can reduce behavioral symptoms while maintaining an acceptable safety profile.
TGR-63 Disease-Modifying Research
TGR-63 is a preclinical small molecule being studied for its ability to interfere with amyloid-related processes and protect neurons. The program represents the company's longer-term effort to address underlying disease biology.
Cannabinoid and Small-Molecule Expertise
IGC's research incorporates cannabinoid pharmacology and other small-molecule approaches. The company uses formulation, preclinical, and clinical-development capabilities to advance candidates for central nervous system disorders.
AI and Biomarker Platforms
The MINT-AD and AHA initiatives apply artificial intelligence to Alzheimer's diagnosis, clinical-trial analysis, and drug development. These tools are intended to complement the therapeutic pipeline with digital and biomarker capabilities.
Future catalysts
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of IGC Pharma, Inc. (IGC)?
IGC Pharma, Inc. (IGC) most recently closed at 0.27 USD, a +0.41% move versus the previous session.
What is the market cap of IGC Pharma, Inc. (IGC)?
IGC Pharma, Inc. currently has a market capitalization of 29M USD on BioPharmSignal.
What does IGC Pharma, Inc. do?
Alzheimer's Disease Drug Developer IGC Pharma develops therapies and digital tools for Alzheimer's disease and related neuropsychiatric symptoms. Its portfolio includes a clinical-stage treatment for agitation and earlier disease-modifying research. IGC-AD1 for Agitation IGC-AD1 is an oral formulation being evaluated for agitation in patients with...
On which exchange is IGC stock listed?
IGC Pharma, Inc. (IGC) is associated with NYSE, United States, Biopharma.
What is IGC-AD1?
IGC-AD1 for Agitation IGC-AD1 is an oral formulation being evaluated for agitation in patients with Alzheimer's disease.
Which conditions is IGC Pharma, Inc. targeting with IGC-AD1?
Alzheimer's Disease Drug Developer IGC Pharma develops therapies and digital tools for Alzheimer's disease and related neuropsychiatric symptoms. Its portfolio includes a clinical-stage treatment for agitation and earlier disease-modifying research. IGC-AD1 for Agitation IGC-AD1 is an oral formulation being evaluated for agitation in patients with...
What is TGR-63?
TGR-63 Disease-Modifying Research TGR-63 is a preclinical small molecule being studied for its ability to interfere with amyloid-related processes and protect neurons.
What is MINT-AD?
AI and Biomarker Platforms The MINT-AD and AHA initiatives apply artificial intelligence to Alzheimer's diagnosis, clinical-trial analysis, and drug development.